MONOCLONAL ANTIBODY BC8
Dlbcl-Ci
Memorial Sloan Kettering Cancer Centermonoclonal_antibodyEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 24/ 100
- Competitive Position
- 95/ 100
Competitive context
15 Active assets in the Dlbcl-Ci cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
PREDNISONE TABLETS Northwestern University | Phase 2/3 | BB |
VINCRISTINE SULFATE Northwestern University | Phase 2/3 | BB |
Inno-206 Northwestern University | Phase 2/3 | BB |
Cyclophosphamide Mayo Clinic | Phase 2/3 | B |
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER Mayo Clinic | Phase 2/3 | B |
View all 15 →
Same molecule, other indications
MONOCLONAL ANTIBODY BC8 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →